Chorionic Gonadotrophin
Treatment of anovulatory infertility, infertility, combined deficiency of human growth hormone and gonadotrophins, hypogonadism or delayed puberty, and assisted reproductive technology.
Access path
- Mar 2017Recommended
- PBS listing · Restricted
From the public summary
5.1 The PBAC recommended the listing of chorionic gonadotrophin vials containing powder for injection corresponding to 1500 IU and 5000 IU under the same conditions as the currently PBS-listed chorionic gonadotrophin ampoules.PSD · Mar 2017
5.2 The PBAC noted that there would be no financial impact to the PBS as a result of the listing as the new form would be listed at the same price as the currently listed form of chorionic gonadotrophin. The PBAC noted advice from the Department that listing of the new form would trigger a 16% statutory price reduction.PSD · Mar 2017
Cost-effectiveness
Not modelled — minor submission for new formulation (powder vial) of existing drug with direct substitution and no additional financial impact.
Decision context
PopulationPatients with anovulatory infertility, infertility associated with hypogonadotrophic hypogonadism or isolated luteinising hormone deficiency, combined deficiency of human growth hormone and gonadotrophins, hypogonadism or delayed puberty (males aged ≥16 years), or undergoing assisted reproductive technology.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2017 | Recommended | — | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC specifies anovulatory infertility and hypogonadotrophic hypogonadism; TGA label broader, including cryptorchism and general sterility.